Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AL7099A
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
AL7099A is an experimental small molecule drug candidate with the chemical formula C14H17N3O5S3. It has been identified as a high promiscuity inhibitor of cytochrome P450 enzymes, particularly CYP3A4. The compound is under investigation primarily as a discovery agent and has not reached advanced clinical development or received regulatory approval for any indication. Its mechanism of action includes inhibition of cytochrome P450 3A4 (CYP3A4), which may impact the metabolism of other drugs. There are no known approved uses or marketed formulations for AL7099A at this time[1][2][3].
- Other names
- RMOXCYSVWCHXII-GFCCVEGCSA-N
02
Targets
CYP3A4 (Cytochrome P450 3A4)
Beyond the preview
Go deeper on AL7099A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AL7099A.